Block admission six monthly return

RNS Number : 4463G
Fusion Antibodies PLC
01 April 2022
 

1 April 2022

 

Fusion Antibodies plc

("Fusion" or the "Company")

 

Block admission six monthly return

 

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces the following information in connection with its block admission pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies.

 

 

Name of company:

 

Fusion Antibodies plc

Name of scheme:

 

Historic options, EMI and Unapproved Employee Share Option Scheme, as announced on 27 September 2021

 

Period of return:

 

From 1 October 2021 to 1 April 2022

Number and class of securities not issued under the scheme at the beginning of the period:

917,083 ordinary shares of 4 pence each in the Company ("Ordinary Shares")

 

Number of securities issued under the scheme during the period:

 

120,000 Ordinary Shares

 

Number of options under the scheme that have lapsed during the period:

Options over 10,000 Ordinary Shares

Balance under the scheme of securities not yet issued at the end of the period:

 

787,083 Ordinary Shares

Number and class of securities originally admitted and the date of admission:

 

917,083 Ordinary Shares on 27 September 2021

Contact name and telephone number:

 

James Fair, CFO via Walbrook PR

+44 (0)20 7933 8780

 

 

Enquiries: 

 

Fusion Antibodies plc

www.fusionantibodies.com

Simon Douglas, Chairman

James Fair, Chief Financial Officer

Via Walbrook PR



Allenby Capital Limited

Tel: +44 (0)20 3328 5656 

James Reeve/Vivek Bhardwaj (Corporate Finance)

Tony Quirke (Sales and Corporate Broking)




Walbrook PR

Tel: +44 (0)20 7933 8780 or  fusion@walbrookpr.com

Anna Dunphy

Mob: +44 (0)7876 741 001

Paul McManus

Mob: +44 (0)7980 541 893

 

About Fusion Antibodies plc

 

Fusion is a Belfast-based Collaborative Research Organisation ("CRO") company, listed on AIM, providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

 

Fusion provides a broad range of services in antibody generation, development, characterisation, optimisation, and small-scale production. These services include antigen expression, purification and sequencing, antibody humanisation using Fusion's proprietary CDRxTM platform and cell line development, producing antibody generating stable cell lines optimised for use downstream by the customer to produce material for clinical trials. Since 2012, the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects for its international customer base, which has included eight of the top 10 global pharmaceutical companies by revenue.

 

At every stage, our client's vision is central to how we work in combining the latest technological advances with cutting edge science. In this work our world-class humanization and antibody optimization platforms harness the power of natural somatic hypermutation (SHM) to ensure the best molecule goes to the clinic. Fusion Antibodies' growth strategy is based on enabling Pharma and Biotech companies get to the clinic more effectively, using molecules with optimized therapeutic profile and enhanced potential for successful development and approval and, ultimately, on speeding up the drug discovery and development process. Fusion's use of SHM to create a fully human antibody library to capture the human antibody repertoire will address a continuing market need in antibody discovery,

 

Fusion Antibodies' emphasis on antibody therapeutics is based on the size and growth rate in the sector, with the market valued at $135.4 billion in 2018 and forecast to surpass $300 billion by 2025, a CAGR of 14.26%. As of May 2021, there were 100 approved antibody therapies on the market and more than 570 antibody therapies in clinical development.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BLRBKCBPQBKDDNB
UK 100

Latest directors dealings